Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) (NCT06456346)
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.
Who can join: Review the eligibility criteria below.
Location: Palo Verde Cancer Specialists ( Site 0052) — Glendale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (171 Sites)
Showing the first 25 of 171 sites.
- Palo Verde Cancer Specialists ( Site 0052) — Glendale, Arizona
- Los Angeles Cancer Network ( Site 0025) — Glendale, California
- Stanford Cancer Center ( Site 0024) — Palo Alto, California
- Exempla Lutheran Medical Center ( Site 0014) — Golden, Colorado
- Yale University School of Medicine ( Site 0051) — New Haven, Connecticut
- Parkview Research Center at Parkview Regional Medical Center ( Site 0006) — Fort Wayne, Indiana
- University of Michigan ( Site 0003) — Ann Arbor, Michigan
- Optum Care Cancer Center ( Site 0053) — Las Vegas, Nevada
- Levine Cancer Institute ( Site 0009) — Charlotte, North Carolina
- Duke University Health System (DUHS) ( Site 0012) — Durham, North Carolina
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013) — Winston-Salem, North Carolina
- The Ohio State University Wexner Medical Center ( Site 0028) — Columbus, Ohio
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8005) — Eugene, Oregon
- Oregon Health & Science University ( Site 0018) — Portland, Oregon
- TriStar Bone Marrow ( Site 7000) — Nashville, Tennessee
- Texas Oncology - West Texas ( Site 8003) — Amarillo, Texas
- Texas Oncology - DFW ( Site 8006) — Dallas, Texas
- University of Texas MD Anderson Cancer Center ( Site 0026) — Houston, Texas
- University of Texas Health Science Center at San Antonio ( Site 0021) — San Antonio, Texas
- Texas Oncology - Gulf Coast ( Site 8008) — Webster, Texas
- University of Virginia ( Site 0020) — Charlottesville, Virginia
- VCU Health Adult Outpatient Pavillion ( Site 0008) — Richmond, Virginia
- Hospital Universitario Austral ( Site 0101) — Pilar, Buenos Aires
- Hospital Italiano de Buenos Aires ( Site 0102) — ABB, Buenos Aires F.D.
- C.I.C.E. 9 de Julio ( Site 0104) — San Miguel de Tucumán, Tucumán Province
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Essential Thrombocythemia
- A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET — Birmingham, Alabama
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance — Scottsdale, Arizona
- IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) — Miami, Florida
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) — Glendale, Arizona
- Ruxolitinib in Thrombocythemia and Polycythemia Vera — Boston, Massachusetts
Explore by condition: All Essential Thrombocythemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.